Results 11 to 20 of about 4,938,261 (300)

Recent advances in therapies for primary myelofibrosis. [PDF]

Fac Rev, 2023
Primary myelofibrosis (PMF), polycythemia vera (PV) and essential thrombocythemia (ET) form the classical BCR-ABL1-negative myeloproliferative neoplasms (MPNs) that are driven by a constitutive activation of JAK2 signaling.
Vainchenker W, Yahmi N, Havelange V, Marty C, Plo I, Constantinescu SN.   +5 more
europepmc   +2 more sources

Primary myelofibrosis: spectrum of imaging features and disease-related complications

Insights into Imaging, 2019
Primary myelofibrosis is a chronic clonal stem cell disorder that results in a build-up of marrow fibrosis and dysfunction, hypermetabolic states, and myeloid metaplasia.
Sheng Fei Oon, Dalveer Singh, Teng Han Tan, Allan Lee, Geertje Noe, Kate Burbury, Joseph Paiva   +6 more
doaj   +2 more sources

Primary myelofibrosis: 2023 update on diagnosis, risk‐stratification, and management

American journal of hematology/oncology, 2023
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell‐derived clonal myeloproliferation that is often but not always accompanied by JAK2, CALR, or MPL mutations; additional features include bone marrow reticulin ...
A. Tefferi
semanticscholar   +1 more source

Higher estimated plasma volume status is associated with increased thrombotic risk and impaired survival in patients with primary myelofibrosis

Biochemia Medica, 2023
Introduction Blood plasma represents a large reservoir of cytokines and other mediators of inflammation. Higher estimated plasma volume status (ePVS) has been shown to correlate with increased thrombotic risk in polycythemia vera patients, but its ...
M. Lucijanić, I. Krečak, E. Sorić, A. Sabljić, D. Galušić, H. Holik, V. Periša, Martina Morić Perić, I. Zekanović, R. Kušec   +9 more
semanticscholar   +1 more source

Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis

Blood Cancer Journal, 2022
Dear Editor , Cytopenias are frequent and distinctive features of primary myelo fi brosis (PMF). Anemia is the most common, has consistently been associated with shortened survival, and is an integral component of prognostic models (IPSS, DIPSS/-plus ...
G. Coltro, F. Mannelli, G. G. Loscocco, C. Mannarelli, G. Rotunno, C. Maccari, Fabiana Pancani, A. Atanasio, A. Vannucchi, P. Guglielmelli   +9 more
semanticscholar   +1 more source

Therapeutic activity of GARP:TGF-β1 blockade in murine primary myelofibrosis

Blood, 2022
Key Points • Anti-GARP:TGF-β1 mAb exerts antitumor activity in myeloproliferative neoplasms by selectively blocking Treg-derived TGF-β1.• Targeting Treg functions is feasible and has immune-mediated therapeutic activity in blood cancers.
S. Lecomte, Devreux Julien, Grégoire de Streel, N. van Baren, D. Schröder, Noora Vaherto, Christophe Vanhaver, Christophe Vanderaa, Noémie Dupuis, C. Pecquet, P. Coulie, S. Constantinescu, S. Lucas   +12 more
semanticscholar   +1 more source

IGFBP-6/sonic hedgehog/TLR4 signalling axis drives bone marrow fibrotic transformation in primary myelofibrosis

Aging, 2021
Primary myelofibrosis is a Ph-negative chronic myeloproliferative neoplasm characterized by bone marrow fibrosis and associated with the involvement of several pathways, in addition to bone marrow microenvironment alterations, mostly driven by the ...
L. Longhitano, D. Tibullo, N. Vicario, C. Giallongo, E. La Spina, A. Romano, S. Lombardo, M. Moretti, Francesco Masia, A. R. Coda, S. Venuto, Paolo Fontana, R. Parenti, G. Li Volti, M. Di Rosa, G. Palumbo, A. Liso   +16 more
semanticscholar   +1 more source

AIF1+CSF1R+ MSCs, induced by TNF‐α, act to generate an inflammatory microenvironment and promote hepatocarcinogenesis

Hepatology, EarlyView., 2022
Mesenchymal stem cells subset, educated by TNF‐α, are involved to generate inflammatory microenvironment and promote hepatocarcinogenesis Abstract Background and Aims Increasing evidence suggests that mesenchymal stem cells (MSCs) home to injured local tissues and the tumor microenvironment in the liver.
Chen Zong, Yan Meng, Fei Ye, Xue Yang, Rong Li, Jinghua Jiang, Qiudong Zhao, Lu Gao, Zhipeng Han, Lixin Wei   +9 more
wiley   +1 more source

Impact of the rs1024611 Polymorphism of CCL2 on the Pathophysiology and Outcome of Primary Myelofibrosis

Cancers, 2021
Simple Summary Among myeloproliferative neoplasms, primary myelofibrosis (PMF) is considered the paradigm of inflammation-related cancer development. Host genetic variants such as single nucleotide polymorphisms (SNPs) can affect cytokine/chemokine gene ...
E. Masselli, C. Carubbi, Giulia Pozzi, A. Percesepe, R. Campanelli, L. Villani, G. Gobbi, S. Bonomini, G. Roti, V. Rosti, M. Massa, G. Barosi, M. Vitale   +12 more
semanticscholar   +1 more source

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis

Hepatology, EarlyView., 2022
Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Sandra Torres, Cristina Ortiz, Nadine Bachtler, Wenyi Gu, Leon D. Grünewald, Nico Kraus, Robert Schierwagen, Christoph Hieber, Caroline Meier, Olaf Tyc, Maximilian Joseph Brol, Frank Erhard Uschner, Bart Nijmeijer, Christoph Welsch, Marie‐Luise Berres, Carmen Garcia‐Ruiz, Jose Carlos Fernandez‐Checa, Christian Trautwein, Thomas J. Vogl, Stefan Zeuzem, Jonel Trebicka, Sabine Klein   +21 more
wiley   +1 more source